Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

Biotechnology

Zai Lab

Samantha Du

Christine Chiou

Robert J. Brown

Yajing Chen

Rafael G. Amado

Peter Huang

Jonathan Wang

William Liang

Harald Reinhart

F. Ty Edmondson

James Yan

Jim Massey

Josh Smiley

Ann E. Beasley

Ning Xu

Zai Lab's Founding Team includes Samantha Du.

Founding Team

Leadership Team

CEO and Executive Team

Board of Directors

Founding Team

About

Team members

Other teams at Zai Lab

Leadership Team

CEO and Executive Team

Board of Directors